Table 1 Baseline clinical characteristics of patients included in the study
Characteristics | Overall Patients (n = 97) N (%) | Recurrence (n = 58) N (%) | No recurrence (n = 39) N (%) | P-value |
|---|---|---|---|---|
Age at diagnosis (years) | ||||
 Mean ± Standard deviation | 48.81 ± 9.186 | 48.74 ± 9.484 | 48.92 ± 8.845 | 0.924 |
 Range | 26–68 | 30–67 | 26–68 | |
Menstrual status | ||||
 Premenopausal | 30 (30.9) | 19 (32.8) | 11 (28.2) | 0.812 |
 Postmenopausal | 52 (53.6) | 31 (53.4) | 21 (53.8) | |
 Perimenopausal | 15 (15.5) | 8 (13.8) | 7 (17.9) | |
Hormonal receptors status | ||||
 ER + PR +  | 72 (74.2) | 47 (81) | 25 (64.1) | 0.08 |
 ER + PR- | 12 (12.4) | 6 (10.3) | 6 (15.4) | |
 ER-PR +  | 10 (10.3) | 3 (5.2) | 7 (17.9) | |
 Unknown | 3 (3.1) | 2 (3.4) | 1 (2.6) | |
HER2 status | ||||
 Positive | 20 (20.6) | 14 (24.1) | 6 (15.4) | 0.296 |
 Negative | 60 (61.9) | 32 (55.2) | 28 (71.8) | |
 Unknown | 17 (17.5) | 12 (20.7) | 5 (12.8) |  |
Nodal status | ||||
 0 | 21 (21.6) | 8 (13.8) | 13 (33.3) | 0.03 |
 1–3 | 25 (25.8) | 14 (24.1) | 11 (28.2) | |
  ≥ 4 | 46 (47.4) | 33 (56.9) | 13 (33.3) | |
 Unknown | 5 (5.2) | 3 (5.2) | 2 (5.1) | |
Tumor size | ||||
 Tis | 1 (1) | 0 (0) | 1 (2.6) | 0.387 |
 T1 | 8 (8.2) | 3 (5.2) | 5 (12.8) | |
 T2 | 56 (57.7) | 35 (60.3) | 21 (53.8) | |
 T3 | 19 (19.6) | 13 (22.4) | 6 (15.4) | |
 T4 | 6 (6.2) | 3 (5.2) | 3 (7.7) | |
 Unknown | 7 (7.2) | 4 (6.9) | 3 (7.7) | |
Operative surgery | ||||
 Mastectomy | 89 (91.8) | 51 (87.9) | 38 (97.4) | 0.138 |
 Breast-conserving | 8 (8.2) | 7 (12.1) | 1 (2.6) | |
Other adjuvant therapies | ||||
 Chemotherapy | 11 (11.3) | 7 (12.1) | 4 (10.3) | 0.459 |
 Chemotherapy + Radiotherapy | 85 (87.6) | 51 (87.9) | 34 (87.2) | |
 Neither | 1 (1) | 0 (0) | 1 (2.6) | |
Hot flashes | ||||
 Yes | 40 (41.2) | 19 (32.8) | 21 (53.8) | 0.061 |
 No | 55 (56.7) | 37 (63.8) | 18 (46.2) | |
 Unknown | 2 (2.1) | 2 (3.4) | 0 (0) | |